The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New spin-out company

26 Nov 2014 07:00

RNS Number : 9910X
Frontier IP Group plc
26 November 2014
 



 

 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Company")

 

New Spin-out Company - Cambridge Simulation Solutions Limited

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that it has received a stake in Cambridge Simulation Solutions Ltd ("Cambridge Simulation"), a spin-out company from the Department of Chemical Engineering and Biotechnology at the University of Cambridge (the "Department").

Frontier IP has entered into an agreement with Cambridge Simulation in which it provides advisory and business development services in return for which it has received a 40% equity stake in the new spin-out. Cambridge Simulation has been formed to exploit the technology developed by Dr. Vassilios Vassiliadis, a Senior Lecturer at the Department. Dr. Vassiliadis has developed a method to simulate and control complex chemical processes and Frontier IP's role will be to support the licensing and commercialisation of this technology, which potentially has a wide range of commercial applications in industry, including the food and pharmaceutical sectors.

The Department of Chemical Engineering and Biotechnology at the University of Cambridge is a leading global research department, with Chemical Engineering ranked the best in the world outside the US and 4th in the world including the US (QS World University Rankings by Subject 2014). Working effectively with industry is a core strength of the Department, as is progressing novel technologies through spinout companies and licensing agreements to ultimate launch of marketed products.

Neil Crabb, Chief Executive of Frontier IP, said,

"This collaboration with Dr. Vassilios Vassiliadis represents an exciting new opportunity for Frontier IP. We have in-depth experience in commercialising IP and we look forward to working with Dr. Vassiliadis and the Department of Chemical Engineering and Biotechnology at the University of Cambridge to maximise the potential of the existing and the upcoming IP."

Dr. Vassiliadis, said,

"The aim of Cambridge Simulation is to produce a rapid integrator engine suitable for a range of applications and industries, including Chemical Engineering, Biotechnology, Biomedical, Pharmaceuticals, Aerospace and Microelectronics. I'm delighted to be entering into this collaboration with Frontier IP."

Professor Nigel Slater at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, said,

"The Department of Chemical Engineering and Biotechnology at the University of Cambridge fuses leading-edge biotechnology research with chemical engineering skills within an ethos of commercial awareness and exploitation. Broadly, our research strategy targets sustainable reaction engineering, product engineering and healthcare and the Department's activities are structured to provide novel solutions to these challenges. I welcome the launch of this company, as an example of the Department's innovative spirit in tackling the issues of our time."

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Jon Levinson / Lucy Williams

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

 

 

Notes to Editor:

 

Frontier IP Group plc ("Frontier IP") specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes. www.frontierip.co.uk.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMMZMNKLGDZM
Date   Source Headline
15th Nov 20184:08 pmRNSDirector Dealing
15th Nov 201812:37 pmRNSGrant of Options
15th Nov 201810:05 amRNSExscientia acquires Kinetic Discovery
15th Nov 20189:30 amRNSPlacing to raise £2.49 million
15th Nov 20189:25 amRNSFinal Results
30th Oct 20187:00 amRNSSecond Portuguese spin out: Des Solutio
19th Oct 20187:00 amRNSMolendotech signs collaboration agreement with G's
5th Oct 20187:00 amRNSDIT hails Frontier IP's Portuguese success
27th Sep 20187:00 amRNSChange of Adviser
26th Sep 20185:12 pmRNSDirector Declaration
24th Sep 20182:30 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSAmprologix to develop new antibiotics with Ingenza
18th Sep 20181:56 pmRNSAlusid raises £1.34m to scale up manufacturing
17th Sep 20187:00 amRNSAB Sugar Head of Innovation joins Frontier IP
30th Aug 201812:39 pmRNSHolding(s) in Company
15th Aug 20187:00 amRNSTVG awarded £50,000 anti-bacterial vaccine grant
7th Aug 20187:00 amRNSPortfolio news - first Portuguese spin out
6th Aug 20187:00 amRNSFieldwork Robotics agreement with Hall Hunter
2nd Aug 20187:00 amRNSFrontier IP partners with UK DIT in Portugal
16th Jul 20187:00 amRNSTarsis Collaboration with Crop-Protection Company
11th Jul 20187:00 amRNSInnovate UK grant for Pulsiv Solar
19th Jun 20187:00 amRNSCambridge Material Testing Solutions
15th May 20187:00 amRNSPalintest launches Molendotech bathing water test
18th Apr 20184:09 pmRNSHolding(s) in Company
9th Apr 20188:25 amRNSIncreased Equity Holding in Fieldwork Robotics
27th Mar 20187:00 amRNSHALF-YEAR RESULTS, 6 MONTHS TO 31 DECEMBER 2017
26th Mar 20187:00 amRNSTeam Expansion and London Office
19th Feb 20187:00 amRNSPortfolio News - Molendotech Secures First Funding
29th Jan 20187:00 amRNSCapital Markets Day
29th Jan 20187:00 amRNSPortfolio News - Molendotech Collaboration
18th Dec 20177:00 amRNSCapital Markets Day
7th Dec 201711:50 amRNSResult of AGM
8th Nov 20177:00 amRNSPosting of Annual Report and Notice of AGM
30th Oct 20175:15 pmRNSHolding(s) in Company
30th Oct 201712:00 pmRNSPortfolio News PulsiV Granted Two US Patents
24th Oct 20177:00 amRNSFinal Results
9th Oct 20177:00 amRNSExscientia Wins Emerging Biotech Company Award
28th Sep 20177:00 amRNSExscientia announces investment from Evotec
25th Sep 20171:12 pmRNSHolding(s) in Company
20th Sep 20177:00 amRNSAlusid extends range at London Design Festival
7th Sep 20177:00 amRNSCSI launches novel sensor system at IFA Berlin
8th Aug 20177:00 amRNSNew Portfolio Company - The Vaccine Group
28th Jul 20173:26 pmRNSHolding(s) in Company
20th Jul 20177:00 amRNSPortfolio News- Nandi Proteins Limited Fundraising
11th Jul 20174:38 pmRNSHolding(s) in Company
5th Jul 20177:00 amRNSNew Portfolio Company - MolEndoTech
3rd Jul 20177:00 amRNSExscientia announces major GSK collaboration
11th May 20177:00 amRNSGrant of Options
9th May 201712:05 pmRNSRoyal Society of Chemistry Nominations
9th May 201711:25 amRNSExscientia announces major Sanofi collaboration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.